布地奈德联合复方异丙托溴铵在上呼吸道感染中的应用价值分析

Application value of budesonide combined with compound of ipratropium bromide and salbutamol in upper respiratory tract infection

目的探讨布地奈德联合复方异丙托溴铵治疗上呼吸道感染(URTI)的疗效,为临床治疗提供参考。方法选取2019年2月至2021年8月广西壮族自治区桂林冶金疗养院收治的60例URTI患者为研究对象,按照随机数字表法分为对照组(30例,予布地奈德治疗)和治疗组(30例,予布地奈德联合异丙托溴铵治疗)。比较两组患者治疗总有效率、症状积分、呼气高峰流量(PEFR)、嗜酸粒细胞直接计数(EOS)、免疫功能指标以及不良反应发生率。结果治疗组患者总有效率比对照组高(P<0.05)。两组患者治疗后症状积分均比治疗前低,且治疗组比对照组低(P<0.05)。两组患者治疗后PEFR高于治疗前、EOS低于治疗前(P<0.05);治疗组患者治疗后PEFR高于对照组,且EOS低于对照组(P<0.05);两组患者治疗后CD3^(+)、CD4^(+)T淋巴细胞百分比及CD4^(+)/CD8^(+)比值比治疗前高,CD8^(+)T淋巴细胞百分比低于治疗前(P<0.05);治疗组患者CD3^(+)、CD4^(+)T淋巴细胞百分比及CD4^(+)/CD8^(+)比值比对照组高,CD8^(+)T淋巴细胞百分比低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论布地奈德联合异丙托溴铵治疗URTI的疗效显著,使患者症状缓解,使不良反应发生率降低,值得临床应用。

Objective To explore the clinical effect of budesonide combined with ipratropium bromide in the treatment of upper respiratory tract infection(URTI),to provide reference for clinical treatment.Methods A total of 60 URTI patients who were treated in Guangxi Zhuang Autonomous Region Guilin Metallurgy Sanatorium from February 2019 to August 2021 were selected as the research objects,and divided into control group(30 cases,treated with budesonide)and treatment group(30 cases,treated with budesonide and compound of ipratropium bromide and salbutamol).The total effective rate,symptom scores,peak expiratory flow rate(PEFR),blood eosinophil counts(EOS),laboratory results and immune function indexes and incidence of adverse reactions were compared between the two groups.Results The total effective rate in the treatment group was higher than that in the control group(P<0.05).The symptom scores of the two groups after treatment were lower than those before treatment;The symptom score of the treatment group was lower than that of the control group(P<0.05).The PEFR in the two groups after treatment were higher than that before treatment,and the EOS was lower than that before treatment(P<0.05).The PEFR in the treatment group was higher than that in the control group after treatment,and the EOS in the treatment group was lower than that in the control group(P<0.05).The percentages of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups after treatment were higher than those before treatment,and the percentage of CD8^(+)was lower than that before treatment(P<0.05).The percentages of CD3^(+),CD4^(+)and the ratio of CD4^(+)/CD8^(+)in the treatment group were higher than that of the control group,and the percentage of CD8^(+)was lower than that of the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The efficacy of budesonide combined with ipratropium bromide in the treatment of upper respiratory tract infection is remarkable,which can relieve the symptoms of patients and reduce the incidence of adverse reactions,which is worthy of clinical application.